On December 19, 2016 10:25 (IST)
Laurus Labs makes active pharmaceutical ingredients or APIs that go into the making a range of medicines, chiefly HIV/AIDS drugs.
On December 08, 2016 16:15 (IST)
Laurus Labs was selling up to Rs 300 crore in new shares and some its shareholders were selling about 24.1 million shares in a price range of Rs 426 to Rs 428 per share.
On December 06, 2016 12:10 (IST)
Hyderabad-based pharma company Laurus Labs launched its initial public offer (IPO) on Tuesday to raise Rs 1,330 crore from the primary markets.
On December 06, 2016 10:20 (IST)
The anchor investors included Goldman Sachs India, Nomura Trust and Banking, SBI Mutual Fund, DSP BlackRock and ICICI Prudential Mutual Fund.
On December 04, 2016 12:22 (IST)
The IPO is scheduled to open on December 6 and close on December 8.
On October 17, 2016 20:00 (IST)
Hyderabad-based firm had filed IPO papers with Sebi in August. The markets regulator issued its final 'observations' on October 10 on the draft offer documents, which is necessary for any company to launch the public offer.
On July 07, 2016 23:17 (IST)
Indian pharma firms Aurobindo, Emcure, Hetero Labs, Laurus Labs, Lupin and Zydus Cadila are among the seven drug makers which have signed licensing pact with UN-backed Medicines Patent Pool (MPP) for producing HIV and hepatitis C drugs.